Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 179

1.

Mechanisms of N-oleoyldopamine activation of central histaminergic neurons.

De Luca R, Mazur K, Kernder A, Suvorava T, Kojda G, Haas HL, Sergeeva OA.

Neuropharmacology. 2018 Sep 13. pii: S0028-3908(18)30630-0. doi: 10.1016/j.neuropharm.2018.09.006. [Epub ahead of print]

PMID:
30219501
2.

Involvement of the CB2 cannabinoid receptor in cell growth inhibition and G0/G1 cell cycle arrest via the cannabinoid agonist WIN 55,212-2 in renal cell carcinoma.

Khan MI, Sobocińska AA, Brodaczewska KK, Zielniok K, Gajewska M, Kieda C, Czarnecka AM, Szczylik C.

BMC Cancer. 2018 May 23;18(1):583. doi: 10.1186/s12885-018-4496-1.

3.

Effects of CB2 and TRPV1 receptors' stimulation in pediatric acute T-lymphoblastic leukemia.

Punzo F, Manzo I, Tortora C, Pota E, Angelo V, Bellini G, Di Paola A, Verace F, Casale F, Rossi F.

Oncotarget. 2018 Apr 20;9(30):21244-21258. doi: 10.18632/oncotarget.25052. eCollection 2018 Apr 20.

4.

Impacts of cannabinoid receptor ligands on nicotine- and chronic mild stress-induced cognitive and depression-like effects in mice.

Pekala K, Michalak A, Kruk-Slomka M, Budzynska B, Biala G.

Behav Brain Res. 2018 Jul 16;347:167-174. doi: 10.1016/j.bbr.2018.03.019. Epub 2018 Mar 15.

PMID:
29551733
5.

CB2 receptor activation causes an ERK1/2-dependent inflammatory response in human RPE cells.

Hytti M, Andjelic S, Josifovska N, Piippo N, Korhonen E, Hawlina M, Kaarniranta K, Nevalainen TJ, Petrovski G, Parkkari T, Kauppinen A.

Sci Rep. 2017 Nov 23;7(1):16169. doi: 10.1038/s41598-017-16524-w.

6.

The Inhibitory Effects of Cobalt Protoporphyrin IX and Cannabinoid 2 Receptor Agonists in Type 2 Diabetic Mice.

McDonnell C, Leánez S, Pol O.

Int J Mol Sci. 2017 Oct 28;18(11). pii: E2268. doi: 10.3390/ijms18112268.

7.

ACPA and JWH-133 modulate the vascular tone of superior mesenteric arteries through cannabinoid receptors, BKCa channels, and nitric oxide dependent mechanisms.

López-Dyck E, Andrade-Urzúa F, Elizalde A, Ferrer-Villada T, Dagnino-Acosta A, Huerta M, Osuna-Calleros Z, Rangel-Sandoval C, Sánchez-Pastor E.

Pharmacol Rep. 2017 Dec;69(6):1131-1139. doi: 10.1016/j.pharep.2017.06.011. Epub 2017 Jul 1.

PMID:
29128791
8.

Overactive type 2 cannabinoid receptor induces meiosis in fetal gonads and impairs ovarian reserve.

De Domenico E, Todaro F, Rossi G, Dolci S, Geremia R, Rossi P, Grimaldi P.

Cell Death Dis. 2017 Oct 5;8(10):e3085. doi: 10.1038/cddis.2017.496.

9.

Activation of type 2 cannabinoid receptor (CB2R) by selective agonists regulates the deposition and remodelling of the extracellular matrix.

Guan T, Zhao G, Duan H, Liu Y, Zhao F.

Biomed Pharmacother. 2017 Nov;95:1704-1709. doi: 10.1016/j.biopha.2017.09.085. Epub 2017 Oct 6.

PMID:
28958132
10.

Anti-proliferative, pro-apoptotic and anti-invasive effect of EC/EV system in human osteosarcoma.

Punzo F, Tortora C, Di Pinto D, Manzo I, Bellini G, Casale F, Rossi F.

Oncotarget. 2017 Apr 13;8(33):54459-54471. doi: 10.18632/oncotarget.17089. eCollection 2017 Aug 15.

11.

Anti-nociceptive interactions between opioids and a cannabinoid receptor 2 agonist in inflammatory pain.

Yuill MB, Hale DE, Guindon J, Morgan DJ.

Mol Pain. 2017 Jan-Dec;13:1744806917728227. doi: 10.1177/1744806917728227.

12.

Synergistic combinations of the dual enkephalinase inhibitor PL265 given orally with various analgesic compounds acting on different targets, in a murine model of cancer-induced bone pain.

González-Rodríguez S, Poras H, Menéndez L, Lastra A, Ouimet T, Fournié-Zaluski MC, Roques BP, Baamonde A.

Scand J Pain. 2017 Jan;14:25-38. doi: 10.1016/j.sjpain.2016.09.011. Epub 2016 Nov 1.

PMID:
28850427
13.

Activation of cannabinoid receptor type 2 attenuates surgery-induced cognitive impairment in mice through anti-inflammatory activity.

Sun L, Dong R, Xu X, Yang X, Peng M.

J Neuroinflammation. 2017 Jul 19;14(1):138. doi: 10.1186/s12974-017-0913-7.

14.

A selective CB2R agonist (JWH133) restores neuronal circuit after Germinal Matrix Hemorrhage in the preterm via CX3CR1+ microglia.

Tang J, Miao H, Jiang B, Chen Q, Tan L, Tao Y, Zhang J, Gao F, Feng H, Zhu G, Chen Z.

Neuropharmacology. 2017 Jun;119:157-169. doi: 10.1016/j.neuropharm.2017.01.027. Epub 2017 Jan 30.

PMID:
28153531
15.

The Impact of CB2 Receptor Ligands on the MK-801-Induced Hyperactivity in Mice.

Kruk-Slomka M, Banaszkiewicz I, Biala G.

Neurotox Res. 2017 Apr;31(3):410-420. doi: 10.1007/s12640-017-9702-4. Epub 2017 Jan 30.

16.

Regulation of cannabinoid CB2 receptor constitutive activity in vivo: repeated treatments with inverse agonists reverse the acute activation of JNK and associated apoptotic signaling in mouse brain.

Salort G, Álvaro-Bartolomé M, García-Sevilla JA.

Psychopharmacology (Berl). 2017 Mar;234(6):925-941. doi: 10.1007/s00213-017-4537-5. Epub 2017 Jan 26.

PMID:
28127623
17.

Cannabinoids: Possible agents for treatment of psoriasis via suppression of angiogenesis and inflammation.

Norooznezhad AH, Norooznezhad F.

Med Hypotheses. 2017 Feb;99:15-18. doi: 10.1016/j.mehy.2016.12.003. Epub 2016 Dec 14.

PMID:
28110689
18.

Attenuation of Cocaine-Induced Conditioned Place Preference and Motor Activity via Cannabinoid CB2 Receptor Agonism and CB1 Receptor Antagonism in Rats.

Delis F, Polissidis A, Poulia N, Justinova Z, Nomikos GG, Goldberg SR, Antoniou K.

Int J Neuropsychopharmacol. 2017 Mar 1;20(3):269-278. doi: 10.1093/ijnp/pyw102.

19.

PKCβII-mediated cross-talk of TRPV1/CB2 modulates the glucocorticoid-induced osteoclast overactivity.

Bellini G, Torella M, Manzo I, Tortora C, Luongo L, Punzo F, Colacurci N, Nobili B, Maione S, Rossi F.

Pharmacol Res. 2017 Jan;115:267-274. doi: 10.1016/j.phrs.2016.11.039. Epub 2016 Dec 2.

PMID:
27919827
20.

Cannabinoid Type-2 Receptor Drives Neurogenesis and Improves Functional Outcome After Stroke.

Bravo-Ferrer I, Cuartero MI, Zarruk JG, Pradillo JM, Hurtado O, Romera VG, Díaz-Alonso J, García-Segura JM, Guzmán M, Lizasoain I, Galve-Roperh I, Moro MA.

Stroke. 2017 Jan;48(1):204-212. doi: 10.1161/STROKEAHA.116.014793. Epub 2016 Nov 29.

PMID:
27899748

Supplemental Content

Loading ...
Support Center